These trials have addressed breast cancer, colon cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, and urothelial cancer, utilizing various mTOR inhibitors such as rapamycin, everolimus, metformin, and sirolimus. This evidence concerns the gene MTOR and ovarian cancer.